• The Gummy Project (GUMY) has received a purchase order from the 5-star luxury Four Seasons Hotel San Francisco
  • The company will supply gummies for each of the hotel’s 277 guest room mini-bars
  • A staple in Bay Area luxury, Four Seasons Hotel San Francisco has been awarded the coveted Forbes Travel Guide Five Stars for the past 19 consecutive years
  • GUMY sells low sugar, plant based gummy products while raising money (and awareness) to support endangered keystone species
  • The Gummy Project Inc. (GUMY) is down 33.33 per cent, trading at C$0.01 per share at 11:38 am ET

The Gummy Project (GUMY) has received a purchase order from the 5-star luxury Four Seasons Hotel San Francisco.

The company will supply gummies for each of the hotel’s 277 guest room mini-bars.

Charlie Lamb, President & CEO of GUMY, commented on the announcement.

“We are thrilled to continue our strategic expansion in the U.S. It’s an honour to be selected by the luxury 5-star Four Seasons Hotel San Francisco to supply our Peachy Bees and Watermelon sharks. We look forward to developing a long-term relationship with the hotel. Besides being world-class, they also share our commitment to a more sustainable future for everyone.”

GUMY received the purchase order from the Four Seasons Hotel San Francisco on September 12, 2022. The hotel has maintained Five Stars with the world-renowned authority in genuine Five Star service, Forbes Travel Guide. A staple in Bay Area luxury, Four Seasons Hotel San Francisco has been awarded the coveted Forbes Travel Guide Five Stars for the past 19 consecutive years.

The Gummy Project is a growing community of individuals and organizations who believe small contributions can add up to something big. It sells low-sugar, plant-based gummy products while raising money (and awareness) to support endangered keystone species.

The Gummy Project Inc. (GUMY) is down 33.33 per cent, trading at C$0.01 per share at 11:38 am ET.


More From The Market Online

Rapid Dose Therapeutics collaborates with NFL

Rapid Dose Therapeutics (CSE:DOSE) reveals a collaboration with the National Football League (NFL) for a funded clinical trial program.

@ the Bell: Weak bank earnings pummel TSX

Canada’s largest centre dropped nearly 1 per cent on Wednesday as Treasury yields firmed ahead of key U.S. inflation data.

ESGold acquires 39 mining claims in Quebec

ESGold (CSE:ESAU) reveals it has added 39 mining claims to its portfolio in Quebec totaling 2,286 hectares.